The efficacy of high-dose cabergoline treatment of prolactinomas resistant to standard doses: a clinical observation

Hyperprolactinemia (HP) is one of the most common neuroendocrine disorders. In 60% of cases, pathological HP is caused by pituitary prolactin-secreting adenoma. Therapy with agonists of dopamine type 2 receptors (D2 receptor agonists) is a method of choice for the treatment of pathological HP which...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Zilya A. Kalmykova, Svetlana Y. Vorotnikova, Natalia S. Fedorova, Larisa K. Dzeranova, Ekaterina A. Pigarova, Aleksandr V. Vorontsov
Formato: Artigo
Idioma:Inglês
Publicado em: Endocrinology Research Centre 2019-09-01
Colecção:Ожирение и метаболизм
Assuntos:
hyperprolactinemia
prolactinoma
dopamine receptor agonists
cabergoline
resistance
Acesso em linha:https://www.omet-endojournals.ru/jour/article/view/10243
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados